Dr. Callander on Treatment Considerations in Multiple Myeloma

Natalie S. Callander, MD
Published: Monday, Oct 09, 2017



Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

There are 3 principles to keep in mind when treating patients with relapsed or refractory multiple myeloma, says Callander.

The first is to determine where the patient is in their relapse, the second is to evaluate what type of myeloma the patient has, and the final thing is to consider frailty.
 


Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

There are 3 principles to keep in mind when treating patients with relapsed or refractory multiple myeloma, says Callander.

The first is to determine where the patient is in their relapse, the second is to evaluate what type of myeloma the patient has, and the final thing is to consider frailty.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x